These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 8415211)
21. Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins. Report of a prospective study with 40 cases. Kühnau J; Rüdiger H; Goetz K Exp Clin Endocrinol; 1984 Apr; 83(2):161-7. PubMed ID: 6373318 [TBL] [Abstract][Full Text] [Related]
22. Assessment of diabetic control with Actrapid and Monotard insulins. Harrower AD; Archibald L Practitioner; 1980 Jun; 224(1344):657-8. PubMed ID: 6999491 [No Abstract] [Full Text] [Related]
23. Immunogenicity of bovine, porcine and semisynthetic human insulin. Venekamp WJ; van der Hooft JC; Jacobsen L; van Schaik CL Neth J Med; 1985; 28 Suppl 1():57-8. PubMed ID: 3892343 [No Abstract] [Full Text] [Related]
24. Subcutaneous use of regular human insulin (Novo): pharmacokinetics and continuous insulin infusion therapy. Sonnenberg GE; Kemmer FW; Cüppers HJ; Berger M Diabetes Care; 1983; 6 Suppl 1():35-9. PubMed ID: 6343035 [TBL] [Abstract][Full Text] [Related]
25. Comparative trials with monocomponent (MC) and monospecies (MS) pork insulins in the treatment of diabetes mellitus. Influence on antibody levels, on insulin requirement and on some complications. Andreani D; Iavicoli M; Tamburrano G; Menzinger G; Maltarello C Horm Metab Res; 1974 Nov; 6(6):447-54. PubMed ID: 4476720 [No Abstract] [Full Text] [Related]
26. Efficacy and immunogenicity of human and monocomponent porcine insulin: a randomized double-blind study in diabetic patients previously treated with insulin. Storms GE; Lutterman JA; van 't Laar A Neth J Med; 1986; 29(10):296-302. PubMed ID: 3540688 [No Abstract] [Full Text] [Related]
27. [Purity and antigenicity of the new insulin preparations]. Fankhauser S Schweiz Med Wochenschr; 1976 Sep; 106(36):1218-25. PubMed ID: 996531 [TBL] [Abstract][Full Text] [Related]
28. Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies. Gardner DF; Wilson HK; Podet EJ; Arakaki RF; Nell LJ; Thomas JW; Crane MM; Field JB J Clin Endocrinol Metab; 1986 Apr; 62(4):621-7. PubMed ID: 3512590 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of monocomponent human and porcine insulin in non-insulin dependent diabetes mellitus. Lam HC; Tang KT; Wang JT; Liu YF; Wang LM; Ho LT Zhonghua Yi Xue Za Zhi (Taipei); 1988 Mar; 41(3):217-22. PubMed ID: 3052740 [No Abstract] [Full Text] [Related]
30. Immunogenicity of semisynthetic human insulin. Rogala H; Lawecki J; Czyzyk A Acta Med Pol; 1986; 27(1-2):45-50. PubMed ID: 3551505 [No Abstract] [Full Text] [Related]
31. Metabolic profiles in diabetic subjects treated with human insulin (Novo) and porcine insulin. Colagiuri S; Kotowicz MA; Steinbeck AW; Kidson W Diabetes Care; 1983; 6 Suppl 1():49-52. PubMed ID: 6343039 [TBL] [Abstract][Full Text] [Related]
32. [Use of semisynthetic human insulin in juvenile insulin-dependent diabetes mellitus]. Sacchetti C; Foco A; David O; Balboni R; Gargano P; Cerutti F; Baratono S Minerva Pediatr; 1989 May; 41(5):221-2. PubMed ID: 2677642 [TBL] [Abstract][Full Text] [Related]
33. Circulating antibodies in diabetics treated with conventional and purified insulins. Klaff LJ; Vinik AI; Berelowitz M; Jackson WP S Afr Med J; 1978 Jul; 54(4):149-53. PubMed ID: 694712 [TBL] [Abstract][Full Text] [Related]
34. [Pathogenesis of diabetic microangiopathy. Fluoroangioretinal observations during monocomponent insulin therapy]. Anselmetti G; Antoniotti V; Barbero PL; Castellazzi R; Gamba S; Bruni B Ann Osp Maria Vittoria Torino; 1978; 21(1-6):47-68. PubMed ID: 756200 [TBL] [Abstract][Full Text] [Related]
35. [Semisynthetic human insulin in the treatment of diabetes type I. Preliminary experience]. Vitacolonna E; Consoli A; Capani F Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1849-52. PubMed ID: 6394033 [TBL] [Abstract][Full Text] [Related]
36. A prospective study of the immunogenicity of porcine insulin in HLA-typed new insulin-treated diabetics. Almér LO; Ekberg G; Fankhauser S; Home PD; Worth R; Sailer S; Kurtz AB; Christy M Diabetes Res; 1985 Sep; 2(5):221-4. PubMed ID: 3905185 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. Lam HC; Ho LT; Tang KT; Wang LM; Kwok CF; Liu YF; Hsiao LJ; Li SH Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):346-51. PubMed ID: 2677227 [TBL] [Abstract][Full Text] [Related]
38. Clinical trial with porcine des-Phe B1 insulin. A comparative study with unmodified insulin on therapeutical efficacy, biological activity and immunogenicity. Santeusanio F; Massi-Benedetti M; Clementi A; Calabrese G; Bueti A; Picchio E; Brunetti P Diabete Metab; 1981 Sep; 7(3):173-9. PubMed ID: 7033008 [TBL] [Abstract][Full Text] [Related]
39. [Comparison of a semisynthetic human insulin and swine insulin]. Sailer D; Volkholz HJ; Kolb S; Pichl J Fortschr Med; 1986 Apr; 104(16):340-2. PubMed ID: 3519402 [No Abstract] [Full Text] [Related]
40. Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin. Luyckx AS; Daubresse JC; Jaminet C; Scheen A; Lefebvre PJ Acta Diabetol Lat; 1986; 23(2):101-6. PubMed ID: 3529776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]